| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥185.2B | ¥466.8B | -60.3% |
| Operating Income | ¥-50.1B | ¥211.1B | +211.7% |
| Profit Before Tax | ¥-53.1B | ¥208.9B | +379.8% |
| Net Income | ¥-54.2B | ¥210.7B | +262.2% |
| ROE | -10.5% | 37.1% | - |
FY2025 results show a severe downturn with revenue of ¥18.52B (YoY -60.3%), operating loss of ¥5.01B (prior year profit ¥21.11B), ordinary loss of ¥5.30B (prior year profit ¥20.52B), and net loss of ¥3.75B (prior year profit ¥15.01B). This marks a dramatic reversal from profitability to loss across all income statement levels, with operating margin deteriorating from +45.2% to -27.1%. The company experienced negative operating cash flow of ¥13.28B and free cash flow of ¥15.33B, creating significant liquidity pressure. Balance sheet remains relatively solid with equity ratio of 66.9% and cash holdings of ¥28.68B, though short-term borrowings surged to ¥17.04B from ¥2.59B. The performance deterioration stems primarily from sharp revenue contraction in the Drug Discovery and Development segment combined with high fixed cost burden from R&D (¥5.02B, 27.1% of revenue) and SG&A expenses (¥7.47B, 40.4% of revenue).
Revenue declined 60.3% to ¥18.52B, driven overwhelmingly by the Drug Discovery and Development segment which contracted 91.1% to ¥2.79B from ¥31.31B. This segment historically generated the majority of revenue through licensing arrangements and collaborative research agreements, and the sharp decline suggests completion or non-renewal of major contracts. The Radiopharmaceuticals segment showed resilience with modest growth of 2.4% to ¥15.73B, maintaining stable demand for diagnostic and therapeutic radiopharmaceuticals. Gross profit margin held at 40.6% (¥7.52B), indicating pricing power and production efficiency remained intact despite volume decline. However, operating expenses remained elevated with SG&A at ¥7.47B (down only 18.0% despite 60% revenue decline) and R&D expenses increasing to ¥5.02B (+25.5%), creating severe operating leverage in reverse. The combined ¥12.50B in operating expenses against ¥7.52B gross profit produced the ¥5.01B operating loss. Non-operating items showed finance costs of ¥0.50B partially offset by finance income of ¥0.24B, plus equity method losses of ¥0.04B. Income tax benefit of ¥1.56B (negative expense due to losses) partially mitigated the pre-tax loss of ¥5.31B, resulting in net loss of ¥3.75B. The material ¥1.56B tax benefit versus ¥5.88B tax expense in prior year reflects carryback provisions and deferred tax asset recognition on losses. This represents a revenue down/profit down pattern, with the decline magnified by operational deleverage as fixed costs remained sticky relative to revenue contraction.
Radiopharmaceuticals segment generated revenue of ¥15.73B (+2.4% YoY) with operating income of ¥0.43B, representing the core business at 84.9% of consolidated revenue. Operating margin improved substantially to 2.8% from 1.5% prior year (+76.4% profit growth), demonstrating improved operational efficiency and positive operating leverage in this segment. The segment includes SPECT and PET diagnostic agents plus therapeutic radiopharmaceuticals, with steady demand from medical institutions. Drug Discovery and Development segment revenue collapsed to ¥2.79B (-91.1% YoY) with operating loss of ¥5.36B (prior year profit ¥20.96B), producing a negative operating margin of -191.8%. This segment encompasses PDPS platform-based collaborative research, technology licensing, and proprietary pipeline development. The severe loss reflects the dual impact of revenue loss (likely from expired or scaled-back licensing agreements) combined with continued high investment in research infrastructure and pipeline development. Inter-segment revenue from Radiopharmaceuticals to Drug Discovery totaled ¥1.15B. The stark divergence between segments—one profitable and stable, one deeply unprofitable—highlights business model risks concentrated in the discovery platform monetization strategy.
[Profitability] ROE of -6.9% represents a sharp reversal from prior year's 30.9%, driven by net loss against equity base. Operating margin collapsed to -27.1% from 45.2%, reflecting severe operational deleverage. Gross margin of 40.6% remains reasonable but insufficient to absorb fixed cost burden. R&D intensity stands at 27.1% of revenue, elevated due to revenue denominator compression. [Cash Quality] Cash and equivalents of ¥28.68B decreased ¥19.43B from ¥48.12B, with coverage of short-term borrowings at 1.68x providing adequate near-term liquidity buffer. Operating cash flow turned deeply negative at ¥13.28B outflow, contrasting with ¥23.84B inflow prior year, indicating severe cash consumption. [Investment Efficiency] Asset turnover declined as revenue compressed while asset base remained relatively stable. Working capital deteriorated with receivables increasing ¥0.58B and inventory rising ¥0.52B against declining revenue, suggesting collection and inventory turnover challenges. [Financial Health] Equity ratio of 66.9% remains solid compared to 61.2% prior year, supported by ¥51.53B total equity. Current ratio shows pressure from short-term borrowings surge to ¥17.04B from ¥2.59B, creating refinancing concentration risk. Debt-to-equity ratio increased but remains manageable. Deferred tax assets increased to ¥6.57B from ¥4.73B, reflecting loss carryforward recognition.
Operating cash flow recorded a severe outflow of ¥13.28B versus ¥23.84B inflow prior year, representing a ¥37.12B deterioration. The subtotal before working capital changes was negative ¥5.12B, already below breakeven at the operating income level. Working capital changes further drained ¥8.15B, comprising receivables increase of ¥0.58B, inventory buildup of ¥0.52B, and payables decrease of ¥1.00B, collectively indicating deteriorating operating efficiency and extended cash conversion cycles. The dominant cash outflow item was income tax payment of ¥8.07B, reflecting settlement of prior year's strong profitability. Interest paid totaled ¥0.32B on increased debt levels. Investing cash flow showed ¥2.05B outflow, primarily driven by capital expenditures of ¥1.64B for property, plant and equipment, plus ¥0.30B in investment securities purchases and ¥0.11B in intangible asset acquisitions. Notably absent was the ¥10.94B proceeds from investment securities sales that benefited prior year's investing cash flow. Financing cash flow recorded ¥4.06B outflow, comprising ¥2.64B in long-term debt repayment, ¥0.96B in treasury share purchases for buyback program, and ¥0.39B in lease payments. The combination of operating cash consumption, continued investment, and debt repayment resulted in cash declining ¥19.43B to ¥28.68B. Free cash flow of negative ¥15.33B indicates the company is consuming rather than generating discretionary cash, raising questions about capital allocation sustainability.
Operating income of negative ¥5.01B versus ordinary income of negative ¥5.30B shows non-operating net cost of approximately ¥0.29B, consisting primarily of net finance costs of ¥0.26B (finance costs ¥0.50B less finance income ¥0.24B) plus equity method losses of ¥0.04B. Finance income includes interest and dividend income from investment securities, while finance costs reflect interest on borrowings. Non-operating items represent 1.6% of revenue, a relatively minor impact compared to operating performance. The absence of significant extraordinary gains or one-time items means reported earnings reflect core operational reality. However, earnings quality is compromised by the negative operating cash flow of ¥13.28B substantially exceeding the net loss of ¥3.75B in absolute terms, indicating cash earnings are worse than accounting earnings. This divergence stems from the ¥8.07B tax payment on prior profits plus ¥8.15B working capital deterioration. Accruals analysis shows concerning trends with receivables and inventory increasing against declining sales, suggesting potential collection or demand realization issues. The comprehensive income loss of ¥4.34B versus net loss of ¥3.75B reflects ¥0.59B in other comprehensive losses, primarily from ¥0.52B unrealized losses on equity securities (fair value through OCI) and ¥0.07B remeasurement losses on defined benefit plans. The moderate gap between comprehensive and net income is typical, but overall earnings quality is weak due to the cash flow/earnings divergence and negative trend in operating fundamentals.
Full-year forecast projects revenue of ¥32.0B, operating income of ¥4.6B, and net income attributable to owners of ¥3.0B. Current period achievement rates cannot be determined as the reporting period covers full fiscal year 2025, and these forecasts appear to represent fiscal 2026 guidance. The forecasted revenue of ¥32.0B implies 72.8% growth from FY2025's ¥18.52B, requiring substantial recovery in the Drug Discovery segment or significant new contract wins. Operating income forecast of ¥4.6B assumes a return to profitability with operating margin of 14.4%, a material improvement but well below the 45% achieved in FY2024. The implied operational turnaround requires either revenue recovery approaching ¥30B+ levels with current cost structure, or significant cost rationalization to achieve breakeven at lower revenue. Net income forecast of ¥3.0B implies effective tax rate of approximately 35%, normalizing from the current year's tax benefit scenario. No dividend is forecast (¥0.00), indicating management prioritizes balance sheet preservation over shareholder distributions. The guidance implies confidence in pipeline monetization and contract renewal, though execution risk remains high given the magnitude of required improvement. Key assumptions likely include new licensing agreements, milestone payments, or collaborative research expansions that are not yet publicly detailed.
Annual dividend remains at ¥0.00 for both FY2024 and FY2025, with no distribution planned for FY2026 based on guidance. The absence of dividends is appropriate given negative earnings and cash flow. Payout ratio is not applicable under loss conditions. Share repurchases totaled ¥0.96B during the period despite negative operating cash flow, representing capital allocation that prioritizes shareholder returns over liquidity preservation. The buyback increased treasury stock from ¥1.08B to ¥1.90B, reducing shares outstanding. While the repurchase demonstrates management confidence in long-term value, the timing appears questionable given concurrent operating cash consumption of ¥13.28B and need to preserve liquidity. Total return ratio combining dividends (zero) and buybacks (¥0.96B) against the net loss produces a metric without meaningful interpretation. The company also received ¥0.14B from disposal of treasury shares related to stock compensation exercises. Overall shareholder return policy reflects a tension between maintaining some capital return mechanism (buybacks) while suspending dividends, though financial prudence would suggest conserving all available cash until operating performance stabilizes.
Customer and revenue concentration risk in Drug Discovery segment where single large contracts can dominate revenue and their loss creates severe earnings volatility, as evidenced by the 91% revenue decline when major agreements expired or scaled back. The binary nature of licensing economics creates lumpy, unpredictable cash flows. Liquidity and refinancing risk from short-term borrowing surge to ¥17.04B creates ¥17B maturity concentration requiring refinancing or repayment within 12 months, while operating cash flow remains deeply negative at ¥13.28B, potentially forcing asset sales or dilutive equity raises if operating performance doesn't recover. Technology and pipeline execution risk as Drug Discovery segment operates at ¥5.36B operating loss while consuming high R&D spending (¥5.02B annually), with commercialization timeline and probability for pipeline candidates remaining uncertain, creating potential for sustained cash burn if drug candidates fail to progress or generate licensing revenue.
[Industry Position] (Reference - Proprietary Analysis)
Within the pharmaceutical and biotechnology industry, PeptiDream's metrics show significant divergence from sector medians. ROE of -6.9% falls well below industry median profitability, reflecting the current year loss. The prior year ROE of 30.9% demonstrated capability to exceed industry standards when revenue from platform licensing is realized. Operating margin of -27.1% contrasts sharply with typical pharmaceutical company margins of 15-25%, indicating the company is in an investment/restructuring phase rather than stable operations. The company's equity ratio of 66.9% exceeds the pharmaceutical industry median of approximately 50-60%, demonstrating relatively conservative balance sheet leverage and financial stability despite operational challenges. R&D intensity of 27.1% of revenue (noting denominator compression) is elevated even for biotechnology standards, though absolute R&D spending of ¥5.02B is appropriate for a company with significant discovery platform and pipeline. The negative operating cash flow positions the company in the bottom quartile of industry cash generation, typical of development-stage or restructuring situations. The Radiopharmaceuticals segment operating margin of 2.8% is below typical specialty pharmaceutical margins of 20-30%, suggesting either competitive pricing pressure or operational scale limitations. Revenue volatility driven by licensing economics is characteristic of platform biotechnology companies but represents higher risk profile than traditional pharmaceutical manufacturers with marketed product portfolios. The company's business model—combining a stable but lower-margin radiopharmaceutical manufacturing business with a high-risk, high-reward drug discovery platform—creates a risk-return profile distinct from pure-play pharmaceutical or biotechnology peers.
The financial results reveal a business model under significant stress, with the core Drug Discovery platform segment failing to generate sustainable recurring revenue while maintaining high fixed cost infrastructure. The ¥28.57B revenue decline year-over-year in Drug Discovery indicates dependence on lumpy, non-recurring licensing arrangements rather than stable collaborative research revenue, creating severe earnings volatility. The company's response of continuing high R&D investment (¥5.02B) and executing share buybacks (¥0.96B) while operating cash flow hemorrhages ¥13.28B suggests management confidence in near-term monetization events not yet reflected in current results, though this creates elevated execution risk. The Radiopharmaceuticals segment provides a stable foundation generating ¥15.73B revenue with positive operating income, potentially warranting consideration as a separate strategic asset if Drug Discovery turnaround proves elusive. Balance sheet strength with ¥28.68B cash and 66.9% equity ratio provides a financial cushion to weather 12-18 months of continued losses, though the ¥17.04B short-term borrowing maturity and potential for continued operating cash burn create a time-sensitive imperative for performance recovery. The company's FY2026 guidance implying operating income recovery to ¥4.6B requires belief in imminent Drug Discovery contract wins or pipeline monetization events, introducing binary outcome risk. Structural considerations include whether the PDPS platform can generate sustainable recurring revenue versus episodic licensing windfalls, and whether the cost structure can be rationalized to breakeven at ¥25-30B revenue levels. The R&D investment continuation suggests pipeline assets under development may hold significant option value, though realization timeline remains uncertain. Near-term financial priorities should logically focus on refinancing the short-term debt maturity, controlling working capital consumption (¥8.15B working capital deterioration is unsustainable), and rapidly securing Drug Discovery revenue to restore operating cash flow generation.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.